MCID: CND002
MIFTS: 53

Conduct Disorder

Categories: Mental diseases

Aliases & Classifications for Conduct Disorder

Summaries for Conduct Disorder

Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to antisocial personality disorder and personality disorder. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Related Diseases for Conduct Disorder

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
id Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 30.7 DRD2 DRD4
2 personality disorder 29.1 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
3 pervasive developmental disorder 27.6 COMT DRD4 DRD5 POLR3A SLC6A3 SLC6A4
4 schizophrenia 25.4 ADORA2A COMT DBH DRD2 DRD4 DRD5
5 impulse control disorder 11.3
6 oppositional defiant disorder 11.2
7 cardiomyopathy, dilated, 1e 10.9
8 familial progressive cardiac conduction defect 10.8
9 wolff-parkinson-white syndrome 10.8
10 heart conduction disease 10.8
11 conjunctival pigmentation 10.6 MAOA SLC6A4
12 placenta disease 10.6 DRD2 DRD4
13 ring chromosome 14 syndrome 10.5 COMT MAOA
14 rhinoscleroma 10.5 COMT DRD2
15 intracranial cavernous angioma 10.5 DRD2 SLC6A3 SLC6A4
16 splenic abscess 10.5 DRD2 SLC6A3 SLC6A4
17 multiple personality disorder 10.5 DRD4 MAOA
18 eosinophilia-myalgia syndrome 10.5 DRD2 DRD4 SLC6A3
19 c8 deficiency, type ii 10.5 COMT DRD2 DRD4
20 tinea pedis 10.5 MAOA SLC6A3 SLC6A4
21 uterus intravascular leiomyomatosis 10.4 COMT MAOA SLC6A4
22 ornithosis 10.4 DRD2 MAOA SLC6A4
23 teebi kaurah syndrome 10.4 COMT DRD2
24 intrahepatic gall duct cancer 10.4 COMT MAOA SLC6A4
25 hypertrophy of breast 10.4 DRD4 OXTR SLC6A3
26 chronic dacryoadenitis 10.4 COMT MAOA SLC6A4
27 attention deficit-hyperactivity disorder 10.4
28 simpson-golabi-behmel syndrome 10.4 DBH DRD2 SLC6A3
29 chitty hall webb syndrome 10.4 COMT TPH1
30 pelvic inflammatory disease 10.4 DBH DRD2 SLC6A4
31 chagas disease 10.3 COMT MAOA SLC6A4
32 hyperthyroxinemia 10.3 DRD2 SLC6A4
33 pompholyx 10.3 DRD2 SLC6A4
34 vallecula cancer 10.3 COMT MAOA SLC6A4
35 laryngeal adductor paralysis 10.3 DRD4 SLC6A4 TPH1
36 myopathy, distal, with early respiratory failure, autosomal dominant 10.3 COMT SLC6A3 TPH1
37 parietal foramina 3 10.3 DBH DRD2 SLC6A3
38 suppurative periapical periodontitis 10.3 DRD2 SLC6A4 TPH1
39 perinatal necrotizing enterocolitis 10.2 COMT DRD2 SLC6A3 SLC6A4
40 hypoglycemic coma 10.2 MAOA SLC6A4 TPH1
41 neurogenic bladder 10.2 MAOA SLC6A4
42 bladder hepatoid adenocarcinoma 10.2 DBH DRD2 SLC6A3 SLC6A4
43 acute female pelvic peritonitis 10.2 DBH DRD2 SLC6A3 SLC6A4
44 hereditary multiple exostoses 10.2 COMT DRD2 MAOA SLC6A4
45 anosognosia 10.2 COMT DRD2 OXTR SLC6A4
46 obsessive-compulsive personality disorder 10.1 COMT MAOA SLC6A4 TPH1
47 keratosis 10.1 COMT MAOA SLC6A4 TPH1
48 anodontia 10.1 SLC6A3 SLC6A4
49 alcoholic liver cirrhosis 10.1 ALDH2 DRD2 DRD4 SLC6A4
50 postencephalitic parkinson disease 10.0 DRD2 MAOA SLC6A4 TPH1

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder

Symptoms & Phenotypes for Conduct Disorder

MGI Mouse Phenotypes related to Conduct Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 ADORA2A ALDH2 CAMK2A COMT DBH DRD2
2 homeostasis/metabolism MP:0005376 10.03 MAOA SLC6A3 SLC6A4 TPH1 ADORA2A ALDH2
3 cardiovascular system MP:0005385 10.02 TPH1 ADORA2A COMT DBH DRD2 DRD5
4 endocrine/exocrine gland MP:0005379 9.92 ALDH2 COMT DBH DRD2 DRD5 OXTR
5 integument MP:0010771 9.81 ADORA2A ALDH2 CAMK2A DBH DRD2 OXTR
6 nervous system MP:0003631 9.77 ALDH2 CAMK2A COMT DBH DRD2 DRD4
7 normal MP:0002873 9.17 SLC6A4 DBH DRD2 DRD5 GRIN1 OXTR

Drugs & Therapeutics for Conduct Disorder

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1050)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2 106266-06-2 5073
4
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1 51-64-9 5826
5
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
6
Carbidopa Approved Phase 4,Phase 2,Phase 3,Phase 1 28860-95-9 34359 38101
7
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1 59-92-7 6047
8
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1 97240-79-4 5284627
9
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29110-47-2 3519
10
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
11
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
12
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 2 54739-18-3 3404 5324346
13
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
14
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
15
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 19982-08-2 4054
16
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3 28981-97-7 2118
17
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
18
Clonidine Approved Phase 4,Phase 2,Phase 3,Phase 1 4205-90-7 2803
19
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
20
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
21
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
22
Acamprosate Approved, Investigational Phase 4,Phase 3 77337-76-9 71158
23
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
24
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 34841-39-9, 34911-55-2 444
25
Eszopiclone Approved Phase 4,Phase 3,Phase 2,Phase 1 138729-47-2 969472
26
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
27
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1 2078-54-8 4943
28
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
29
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-78-2 2244
30
Cilostazol Approved Phase 4 73963-72-1 2754
31
Everolimus Approved Phase 4,Phase 3 159351-69-6 6442177
32
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
33
Sirolimus Approved, Investigational Phase 4,Phase 3 53123-88-9 5284616 6436030 46835353
34
Ticlopidine Approved Phase 4,Phase 2,Phase 3 55142-85-3 5472
35
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
36
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
37
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
38
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
39
Cyproheptadine Approved Phase 4 129-03-3 2913
40
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
41
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
42
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 300-62-9 5826 3007
43
Carbamazepine Approved, Investigational Phase 4,Phase 3 298-46-4 2554
44
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
45
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 68-41-7 401 6234
46
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
47
Mifepristone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 84371-65-3 55245
48
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-56-6 439302 53477758
49
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 525-66-6 4946
50
Mirtazapine Approved Phase 4,Phase 2,Phase 3,Phase 1 85650-52-8, 61337-67-5 4205

Interventional clinical trials:

(show top 50) (show all 10000)

id Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg)
4 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
5 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
6 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4 Intuniv
7 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
8 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
9 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4 Memantine
10 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
11 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
12 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4 Aripiprazole
13 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
14 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
15 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
16 Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder Unknown status NCT01130467 Phase 4 methylphenidate;Atomoxetine
17 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
18 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
19 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
20 American Migraine Prevention Study Unknown status NCT00363506 Phase 4
21 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
22 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4 Acamprosate;Placebo
23 Iloperidone in Mixed States of Bipolar Disorder Unknown status NCT02413918 Phase 4 iloperidone
24 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
25 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
26 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
27 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
28 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
29 Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel Unknown status NCT01142440 Phase 4
30 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
31 Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia Unknown status NCT01180855 Phase 4 Placebo;Rozerem 8mg
32 Improving Sleep and Psychological Functioning in People With Depression and Insomnia Unknown status NCT00247624 Phase 4 Eszopiclone;Fluoxetine;Placebo
33 Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures Unknown status NCT02451202 Phase 4 Sugammadex;Rocuronium
34 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
35 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
36 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
37 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4 Varenicline;Placebo
38 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
39 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
40 Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI Unknown status NCT01329601 Phase 4
41 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4
42 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
43 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
44 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
45 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Unknown status NCT01968395 Phase 4 Caspofungin 70 mg
46 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
47 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
48 Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
49 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
50 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: conduct disorder

Genetic Tests for Conduct Disorder

Anatomical Context for Conduct Disorder

MalaCards organs/tissues related to Conduct Disorder:

39
Brain, Heart, Testes, Kidney, Liver, Lung, Eye

Publications for Conduct Disorder

Articles related to Conduct Disorder:

(show top 50) (show all 651)
id Title Authors Year
1
Affect recognition among adolescents in therapeutic schools: relationships with posttraumatic stress disorder and conduct disorder symptoms. ( 28503096 )
2017
2
Investigation of the Changes in the Power Distribution in Resting-State Brain Networks Associated with Pure Conduct Disorder. ( 28717223 )
2017
3
Transitions and Motivations for Substance Misuse in Prison Inmates With ADHD and Conduct Disorder: Validation of a New Instrument. ( 28418789 )
2017
4
Mental health among young adults in prison: the importance of childhood-onset conduct disorder. ( 28357134 )
2017
5
Sex Differences in the Relationship Between Conduct Disorder and Cortical Structure inA Adolescents. ( 28735700 )
2017
6
Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence. ( 28695488 )
2017
7
Taxometric analyses and predictive accuracy of callous-unemotional traits regarding quality of life and behavior problems in non-conduct disorder diagnoses. ( 28427034 )
2017
8
Sex differences in risk-based decision making in adolescents with conduct disorder. ( 28688012 )
2017
9
Alterations of Brain Functional Architecture Associated with Psychopathic Traits in Male Adolescents with Conduct Disorder. ( 28900210 )
2017
10
Short- and long-range functional connectivity density alterations in adolescents with pure conduct disorder at resting-state. ( 28377176 )
2017
11
The reliability, concurrent validity and association with salivary oxytocin of the self-report version of the Inventory of Callous-Unemotional Traits in adolescents with conduct disorder. ( 28628793 )
2017
12
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
13
Familial early infantile epileptic encephalopathy and cardiac conduction disorder: A rare cause of SUDEP in infancy. ( 28697420 )
2017
14
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
15
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
16
Differential neuropsychological functioning between adolescents with attention-deficit/hyperactivity disorder with and without conduct disorder. ( 28292624 )
2017
17
Body Mass Index z-Scores and Weight Status Predict Conduct Disorder Symptoms in Adolescents. ( 28867351 )
2017
18
A systematic review on the prevalence of conduct disorder in the Middle East. ( 28681265 )
2017
19
Neurocognitive characteristics of youth with noncomorbid and comorbid forms of conduct disorder and attention deficit hyperactivity disorder. ( 28636895 )
2017
20
Comorbidities and correlates of conduct disorder among male juvenile detainees in South Korea. ( 28924450 )
2017
21
Empathic skills and theory of mind in female adolescents with conduct disorder. ( 28614490 )
2017
22
Associations between a history of traumatic brain injuries and conduct disorder during youth in a population sample of Canadian adults. ( 28867408 )
2017
23
Facial emotion recognition and eye movement behaviour in conduct disorder. ( 28881001 )
2017
24
Correlates of conduct disorder among inmates of a Nigerian Borstal Institution. ( 27330558 )
2016
25
Gene x environment interactions in conduct disorder: Implications for future treatments. ( 27545756 )
2016
26
Fairness decisions in response to emotions: a functional MRI study among criminal justice-involved boys with conduct disorder. ( 26926604 )
2016
27
Disrupted Topological Patterns of Large-Scale Network in Conduct Disorder. ( 27841320 )
2016
28
Regional grey matter volume and concentration in at-risk adolescents: Untangling associations with callous-unemotional traits and conduct disorder symptoms. ( 27479922 )
2016
29
Stability Subtypes of Callous-Unemotional Traits and Conduct Disorder Symptoms and Their Correlates. ( 27299762 )
2016
30
Does comorbid anxiety counteract emotion recognition deficits in conduct disorder? ( 26934047 )
2016
31
A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. ( 26846227 )
2016
32
Reduced Default Mode Connectivity in Adolescents With Conduct Disorder. ( 27566121 )
2016
33
Mapping the structural organization of the brain in conduct disorder: replication of findings in two independent samples. ( 27306512 )
2016
34
Impaired executive function in 14- to 16-year-old boys with conduct disorder is related to recidivism: A prospective longitudinal study. ( 26864806 )
2016
35
Commentary: Conduct disorder and perceiving harm to others - a reflection on Michalska etA al. (2016). ( 26968315 )
2016
36
Exploring possible association between DI^H genotype (C1021T), early onset of conduct disorder and psychopathic traits in juvenile delinquents. ( 26616837 )
2016
37
Predicting Risky Sexual Behavior: the Unique and Interactive Roles of Childhood Conduct Disorder Symptoms and Callous-Unemotional Traits. ( 27812906 )
2016
38
Acute effects of methylphenidate on impulsivity and attentional behavior among adolescents comorbid for ADHD and conduct disorder. ( 27816696 )
2016
39
Genetic influences on conduct disorder. ( 27350097 )
2016
40
Emotion Regulation Difficulties in Boys with Oppositional Defiant Disorder/Conduct Disorder and the Relation with Comorbid Autism Traits and Attention Deficit Traits. ( 27420110 )
2016
41
Mediating and Moderating Role of Depression, Conduct Disorder or Attention-Deficit/Hyperactivity Disorder in Developing Adolescent Substance Use Disorders: A Population-Based Study. ( 27294778 )
2016
42
Annual Research Review: Transdiagnostic neuroscience of child and adolescent mental disorders - differentiating decision making in attention-deficit/hyperactivity disorder, conduct disorder, depression, and anxiety. ( 26705858 )
2016
43
Ventral striatum and amygdala activity as convergence sites for early adversity and conduct disorder. ( 27694318 )
2016
44
Prospective Investigation of Video Game Use in Children and Subsequent Conduct Disorder and Depression Using Data from the Avon Longitudinal Study of Parents and Children. ( 26820149 )
2016
45
Cortisol levels at baseline and under stress in adolescent males with attention-deficit hyperactivity disorder, with or without comorbid conduct disorder. ( 27280522 )
2016
46
Commentary: Transdiagnostic neuroscience of child and adolescent mental disorders - differentiating decision-making in attention-deficit/hyperactivity disorder, conduct disorder, depression and anxiety. A commentary on Sonuga-Barke etA al. (2016). ( 26889895 )
2016
47
Default mode network activity and neuropsychological profile in male children and adolescents with attention deficit hyperactivity disorder and conduct disorder. ( 27738997 )
2016
48
Long-Term Outcomes of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder: AA Systematic Review and Meta-Analysis. ( 27663939 )
2016
49
Different brain responses during empathy in autism spectrum disorders versus conduct disorder and callous-unemotional traits. ( 26681358 )
2016
50
Investigating the Familial Basis of Heightened Risk-Taking in Adolescents With Conduct Disorder and Their Unaffected Relatives. ( 27031280 )
2016

Variations for Conduct Disorder

Expression for Conduct Disorder

Search GEO for disease gene expression data for Conduct Disorder.

Pathways for Conduct Disorder

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 ALDH2 CAMK2A COMT GRIN1 MAOA SLC6A3
2 12.43 CAMK2A COMT DBH GRIN1 TPH1
3
Show member pathways
12.43 CAMK2A COMT DRD2 DRD4 DRD5 GRIN1
5 12.2 DRD2 DRD4 DRD5 GRIN1
6
Show member pathways
12.1 ADORA2A CAMK2A DRD5 GRIN1 OXTR
7
Show member pathways
12.1 ADORA2A CAMK2A DRD2 DRD5 GRIN1 OXTR
8 12.05 GRIN1 MAOA SLC6A4 TPH1
9
Show member pathways
12.03 CAMK2A DRD2 DRD4 DRD5 GRIN1
10
Show member pathways
11.84 DRD2 DRD4 DRD5
11
Show member pathways
11.83 CAMK2A DRD2 GRIN1 MAOA SLC6A3
12 11.82 MAOA SLC6A4 TPH1
13 11.7 DBH MAOA TPH1
14
Show member pathways
11.61 COMT DBH MAOA
15 11.13 MAOA SLC6A4 TPH1
16 11 DRD2 DRD5
17
Show member pathways
10.99 ADORA2A DBH MAOA SLC6A3 SLC6A4
18
Show member pathways
10.9 COMT DBH MAOA TPH1
19
Show member pathways
10.78 ALDH2 COMT MAOA
20 10.73 COMT MAOA
21
Show member pathways
10.69 ALDH2 MAOA
22
Show member pathways
10.45 ALDH2 COMT MAOA SLC6A3 SLC6A4

GO Terms for Conduct Disorder

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.71 ADORA2A COMT DRD2 GRIN1
2 axon GO:0030424 9.62 ADORA2A COMT DRD2 SLC6A3
3 dendritic spine GO:0043197 9.54 COMT DRD2 GRIN1
4 non-motile cilium GO:0097730 9.46 DRD2 DRD5
5 postsynaptic density GO:0014069 9.46 ADORA2A CAMK2A DRD2 GRIN1
6 neuron projection GO:0043005 9.35 CAMK2A GRIN1 SLC6A3 SLC6A4 TPH1
7 integral component of plasma membrane GO:0005887 9.23 ADORA2A DRD2 DRD4 DRD5 GRIN1 OXTR
8 plasma membrane GO:0005886 10.18 ADORA2A CAMK2A COMT DRD2 DRD4 DRD5
9 integral component of membrane GO:0016021 10.17 ADORA2A COMT DBH DRD2 DRD4 DRD5
10 membrane GO:0016020 10.07 ADORA2A CAMK2A COMT DBH DRD2 DRD4

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.88 COMT OXTR SLC6A3
2 response to drug GO:0042493 9.88 ADORA2A COMT DRD2 OXTR SLC6A3 SLC6A4
3 response to ethanol GO:0045471 9.86 DRD2 GRIN1 SLC6A3
4 cellular calcium ion homeostasis GO:0006874 9.82 DRD4 DRD5 GRIN1
5 locomotory behavior GO:0007626 9.81 ADORA2A DBH DRD2 SLC6A3
6 learning GO:0007612 9.77 COMT DRD5 GRIN1
7 visual learning GO:0008542 9.74 DBH DRD2 GRIN1
8 memory GO:0007613 9.73 DBH GRIN1 OXTR SLC6A4
9 eating behavior GO:0042755 9.71 ADORA2A OXTR
10 arachidonic acid secretion GO:0050482 9.71 DRD2 DRD4
11 behavioral response to cocaine GO:0048148 9.71 DRD2 DRD4
12 synaptic transmission, glutamatergic GO:0035249 9.71 ADORA2A GRIN1
13 response to iron ion GO:0010039 9.7 DRD2 SLC6A3
14 regulation of long-term neuronal synaptic plasticity GO:0048169 9.7 DRD2 GRIN1
15 regulation of neuronal synaptic plasticity GO:0048168 9.7 CAMK2A GRIN1
16 response to pain GO:0048265 9.69 COMT DBH
17 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.69 ADORA2A OXTR
18 negative regulation of protein secretion GO:0050709 9.69 DRD2 DRD4
19 startle response GO:0001964 9.68 DRD2 GRIN1
20 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A3 SLC6A4
21 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.68 DRD2 DRD5
22 maternal behavior GO:0042711 9.67 DBH OXTR
23 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD2 DRD4
24 ammonium transmembrane transport GO:0072488 9.67 SLC6A3 SLC6A4
25 synaptic transmission, dopaminergic GO:0001963 9.67 ADORA2A DRD2 DRD5
26 social behavior GO:0035176 9.67 DRD4 GRIN1 OXTR SLC6A4
27 positive regulation of renal sodium excretion GO:0035815 9.66 ADORA2A DRD2
28 positive regulation of urine volume GO:0035810 9.66 ADORA2A DRD2
29 suckling behavior GO:0001967 9.65 GRIN1 OXTR
30 positive regulation of synaptic transmission, GABAergic GO:0032230 9.65 ADORA2A OXTR
31 behavioral response to ethanol GO:0048149 9.65 DBH DRD2 DRD4
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.64 DRD2 DRD4
33 neurotransmitter catabolic process GO:0042135 9.64 COMT MAOA
34 catecholamine metabolic process GO:0006584 9.63 COMT MAOA
35 regulation of dopamine metabolic process GO:0042053 9.63 DRD4 SLC6A3
36 dopamine metabolic process GO:0042417 9.63 COMT DRD2 DRD4
37 adenohypophysis development GO:0021984 9.62 DRD2 SLC6A3
38 positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway GO:0010579 9.62 ADORA2A DRD5
39 response to cocaine GO:0042220 9.62 DRD2 DRD5 OXTR SLC6A3
40 monoamine transport GO:0015844 9.61 SLC6A3 SLC6A4
41 inhibitory postsynaptic potential GO:0060080 9.61 ADORA2A DRD4
42 dopamine uptake involved in synaptic transmission GO:0051583 9.59 SLC6A3 SLC6A4
43 sperm ejaculation GO:0042713 9.58 OXTR SLC6A4
44 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.58 DRD5 OXTR
45 fear response GO:0042596 9.56 DBH DRD4
46 associative learning GO:0008306 9.56 DBH DRD2 DRD5 GRIN1
47 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.55 DRD2 DRD4
48 response to histamine GO:0034776 9.54 DRD2 DRD4
49 dopamine receptor signaling pathway GO:0007212 9.52 DRD2 DRD4
50 prepulse inhibition GO:0060134 9.46 ADORA2A DRD2 GRIN1 SLC6A3

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 ADORA2A DRD2 DRD4 DRD5 OXTR
2 signal transducer activity GO:0004871 9.65 ADORA2A DRD2 DRD4 DRD5 OXTR
3 drug binding GO:0008144 9.58 DRD2 DRD4 SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD4
6 monoamine transmembrane transporter activity GO:0008504 9.32 SLC6A3 SLC6A4
7 dopamine:sodium symporter activity GO:0005330 9.16 SLC6A3 SLC6A4
8 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
9 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Conduct Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....